Sarah Dolman


Sarah is a Partner at Recon Strategy, focused on science and technology innovations in life sciences and healthcare. Previously, Sarah was a member of the Strategy team at Verily Life Sciences, where she helped develop product roadmaps and commercial launch plans for multiple programs. Sarah’s work in strategy began at the Boston Consulting Group, where she supported biopharma & med-tech clients in prioritizing R&D programs and improving supply-chain operations.  Prior to BCG, Sarah was a Director at Merck, where she led teams in Process Research designing innovative technical solutions to complex synthetic and scale-up challenges for clinical and commercial drug supply. 


Sarah has a PhD in Organic Chemistry from MIT, an MBA from NYU-Stern, and an Hon-BSc from the University of Toronto.

We use cookies
This website collects cookies to deliver better user experience and to analyze our website traffic and performance; we never collect any personal data or target you with ads.